









Analysis of pancreatic endocrine function in patients with IgG4-related 











Endocrine Journal 2014, 61 (8), 765-772 
 1 
 
Analysis of pancreatic endocrine function in patients with IgG4-related diseases, 
in whom autoimmune pancreatitis was ruled out by diagnostic imaging 
 
 





, Kunimasa Yagi, MD, PhD
1
, Mitsuhiro Kawano, MD, PhD
1
, Yukiko Mori, 
MD
1
, Satoko Okazaki, MD
1
, Daisuke Chujo, MD, PhD
1











Department of Internal Medicine, Kanazawa University Graduate School of Medical Science, 
13-1 Takaramachi, Kanazawa, 920-8641, Japan 
2
Department of General Internal Medicine, Kanazawa Medical University, 1-1 Daigaku, 
Uchinada, Kahoku, Ishikawa 920-0293, JAPAN 
 
 
Corresponding author: Kunimasa Yagi 
Address: 13-1 Takaramachi, Kanazawa, 920-8641, Japan 
Phone number: +81-76-265-2264    Fax number: +81-76-234-4251 





IgG4-related disease (IgG4RD) is a newly recognized systemic disease characterized by the 
elevation of serum IgG4 levels and abundant IgG4-positive plasma cell infiltration into the 
involved organs. Few data exist regarding the relationship between diabetes or glucose 
intolerance and IgG4RD in the absence of obvious type 1 autoimmune pancreatitis (AIP). 
Therefore, we are characterizing pancreatic endocrine function in IgG4RD patients with no 
signs of type 1 AIP. 28 patients (12 men, mean age 62.1 years old) were diagnosed as having 
IgG4RD from serum IgG4 levels, histopathology and images. Diagnostic imaging ruled out 
obvious type 1AIP. We used 75g oral glucose tolerance tests (OGTT) and arginine tolerance 
tests (ATT) to evaluate pancreatic endocrine function. Patients’ serum IgG4 and HbA1c 
levels were 603±437 mg/dL and 6.6±1.0%, respectively. The results of OGTT on 23 patients 
showed that 12 patients had diabetes, 4 had impaired glucose tolerance, and 7 had normal 
glucose tolerance. Interestingly, insulin secretion was preserved in most of the patients, even 
in diabetic patients, on OGTT and ATT. Glucagon hyperreactivity was observed in 10 of the 
19 patients who underwent ATT. Twenty-three patients were treated for IgG4RD with 
glucocorticoids. Their HbA1c levels were significantly elevated during the first six months 
of treatment, but improved after twelve months in parallel with glucocorticoid therapy. 
These results demonstrate the high frequency of pancreatic endocrine dysfunction in 
IgG4RD even when there is no indication of AIP, thus revealing that pancreatic endocrine 
dysfunction frequently occurs in IgG4RD without obvious type 1AIP. 
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 IgG4-related disease (IgG4RD) is a newly recognized systemic inflammatory disease 
entity characterized by serum IgG4 level elevation and IgG4-positive plasma cell infiltration 
into the interstitial space of the involved organs [1-6]. Previous reports indicated that involved 
organs were the pancreas (type 1 autoimmune pancreatitis: type 1 AIP), lacrimal and salivary 
glands (chronic sclerosing dacryoadenitis and chronic sclerosing sialadenitis), lungs (interstitial 
pneumonia; pulmonary pseudotumor), kidneys (tubulointerstitial nephritis), retroperitoneum 
(retroperitoneal fibrosis) and prostate [1-6]. Usually, the swelling and enlargement of the 
involved organs, which reflect interstitial inflammation in IgG4RD, are reversible and quickly 
resolved with anti-inflammatory therapy including glucocorticoid [1]. Several studies have 
reported on diabetes in type 1 AIP [7-11] and its remission after glucocorticoid therapy [7-11]. 
 Recently, chronic interstitial inflammation has been thought to play a significant role in the 
initiation and progression of diabetes and its vascular complications [12-15]. So the patients 
with IgG4RD constitute an excellent study population for using observational data to determine 
the prognosis for diabetes with chronic interstitial inflammation. However, few data exist 
regarding the effects of pancreatic endocrine function on IgG4RD, although some patients with 
IgG4RD frequently had diabetes mellitus or glucose intolerance independent from obvious type 
1 AIP and glucocorticoid therapy. Therefore, we examined the pancreatic endocrine function in 




Material and Methods 
Materials 
 Between January 2000 and April 2011, a total of 36 patients were diagnosed as having 
IgG4RD (Figure 1). Twenty-eight patients (15 males, mean age 62.1±9.9 years old) met the 
following inclusion criteria: (1) definite or probable IgG4RD using comprehensive diagnostic 
criteria for IgG4RD 2011 or diagnostic criteria for IgG4-related kidney disease [16,17]; (2) 
possible IgG4RD (if biopsy was not possible because of the difficulty of reaching the affected 
organ(s)) with typical clinical findings and images for IgG4RD [CT, gallium (
67
Ga) 
scintigraphy, or FDG-PET] with successful corticosteroid therapy; (3) without malignant 
disease, vasculitis, tuberculosis, or Castleman’s disease. We excluded (1) patients who were 
diagnosed with type 1 AIP by using ‘Clinical Diagnostic Criteria of Autoimmune Pancreatitis 
2006 in Japan’ [18]; (2) patients who showed accumulation of fluorodeoxyglucose (FDG) in 
the pancreas with positron-emission tomography (PET), and also had inflammation in the 
pancreas; (3) patients with no clinical data about glucose tolerance, such as HbA1c, before 
glucocorticoid therapy (Figure 1). We checked for history of AIP when noting the 
patients’ medical history or from their medical records; those with a history of this 
condition were excluded. However, it was impossible to exclude patients with AIP 
who did not have subjective symptoms. With respect to chronic AIP, patients with 
evidence of pancreatic calcification or pancreatic atrophy on computed 
tomography scans were excluded; pancreatic atrophy was determined according to 
a radiologist’s interpretation. 
 
Evaluations for the pancreatic endocrine function 
 Oral glucose tolerance tests (OGTT) were performed with a standard World Health 
Organization 75g glucose load. Arginine tolerance tests were performed as follows; briefly, 
arginine (L-Arginine hydrochloride, Ajinomoto Pharma, Tokyo, Japan; 10% arginine, 300 
mL/body) was infused for 30 minutes and blood samples were drawn at 0, 15, 30, 45, 60, 90 and 
120 minutes after injection of arginine [19,20]. C-peptide reaction (CPR) and immunoreactive 
glucagon (IRG) concentration were measured each time, and the maximal value was selected to 
evaluate β-cell and α-cell function.  
 All of the subjects were assigned to one of three groups; normal glucose tolerance (NGT), 
impaired glucose tolerance (IGT) and diabetes mellitus (DM) according to World Health 
Organization (WHO) criteria [21]. Briefly, NGT was defined as fasting plasma glucose (FPG) 
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≤ 109 mg/dL and 2 hours postload plasma glucose (2h-PPG) ≤ 139 mg/dL. DM was defined as 
FPG ≥ 126 mg/dl or 2h-PPG ≥ 200 mg/dl. Subjects who didn’t meet either of these criteria were 
designated IGT. 
 Insulin resistance was estimated using the homeostasis model of assessment-insulin 
resistance (HOMA-IR) and Matsuda index [22], and insulin secretion was assessed using the 
homeostasis model of assessment of β-cell function (HOMA-β), insulinogenic index and 
disposition index [23]. The standard value of each index was follows; HOMA-IR≦1.6, 
Matsuda index≦2.5, HOMA-β 40-60%, Insulinogenic index >0.4, and Disposition index 
>1.0. We evaluated the α-cell function by arginine load test. The peak level of IRG equal or 
more over than 300 pg/mL was evaluated as glucagon hyperreactivity. 
 Serum IRI and CPR were determined by enzyme immunoassay (Tosoh Co, Tokyo, Japan). 
Plasma IRG was measured by radioimmunoassay using antiserum monoiodinated 
125
I-labeled 
glucagon (TFB Inc., Tokyo, Japan). HbA1c was measured by high performance liquid 
chromatography (HPLC) using an automated glycohemoglobin analyzer, HLC-723G7 (Tosoh 
Co., Tokyo, Japan). 
 The prevalence ratio for DM and IGT in IgG4RD without obvious type1 AIP was 
evaluated by using the database of the National Health and Nutrition Survey in 2007 by the 
Ministry of Health, Labor and Welfare in Japan [24].  
 
Statistical analysis 
 Statistical analyses were performed using JMP 9.0 (SAS Institute Inc. Cary, NC, USA). 
The data are presented as mean ± standard deviation (SD). Paired-T test, Fisher's exact test and 
Tukey’s HSD test were used for statistical analysis. A p-value of less than 0.05 was considered 
significant for all analysis.  
   This clinical study was approved by the Ethics Committee of the Kanazawa School of 





1. Frequency of DM and IGT in IgG4RD 
The clinical characteristics of all 28 subjects were shown in Table 1. A total of 9 patients 
had a family history of diabetes mellitus and 16 patients did not; the status of family history 
was unknown in 3 patients (added to Table 1). All patients tested negative for anti-glutamic 
acid decarboxylase antibodies. OGTTs were performed in 23 patients, all except those who 
had been previously diagnosed as having diabetes and treated with oral hypoglycemic agents 
(OHAs) (case 2, 7, 20, 23 and 27). According to the results of OGTT of these 23 patients, 12 
were DM (52.1%), 4 were IGT (17.4%) and 7 were NGT (30.4%). Thus, the frequencies of 
DM (n=17) and IGT (n=4) in IgG4RD without obvious type 1 AIP was significantly higher 
than those in the general population, particularly in patients >50 years old, concluded from 
information reported in the database of the database of the National Health and Nutrition 
Survey by the Ministry of Health, Labor and Welfare in Japan (2007) [24] (Table 2). 
  
2. Evaluation of pancreatic endocrine function 
No reduction in insulin secretion was observed in an arginine tolerance test (ATT), 
which was performed in 19 patients (10 DMs, 3 IGTs and 6 NGTs) (Table 3). Actually, delta 
CPR, which reflects intrinsic insulin secretion capacity, in DM was 4.0±2.1, that in IGT was 
3.3±1.6 and that in NGT was 4.5±2.1. On the contrary, glucagon hyperreactivity (peak IRG 
level ≥300 pg/mL) was found in 10 patients on ATT (Table 3). Additionally, delta IRG in DM 
was 353±284, that in IGT was 219±103 and that in NGT was 195±112. 
 
3. Change in glucose intolerance with glucocorticoid therapy in IgG4RD 
 The initial dose of prednisolone was 26.7±7.3 mg/day. Twenty-two patients were followed 
for 12 months after initiation of corticosteroids (Figure 1). The dose of glucocorticoids was 
reduced to 6.8±2.1 mg/day of prednisolone after 12 months. Actually, seven patients had 
changes in their treatment for diabetes after glucocorticoid therapy. In 11 patients taking 
medication for diabetes, 2 patients switched from OHAs to insulin, 4 patients continued OHAs 
or insulin, and the remaining 5 patients started medication for diabetes with OHAs or insulin. 
Of the 11 patients who did not receive medication for diabetes, 4 patients were DM, 2 were IGT, 
and 5 were NGT.  Average HbA1c levels of all subjects changed from 6.4±0.8% at baseline to 
6.8±1.0% at 3 months (p=0.0368). Surprisingly, their HbA1c level declined to 6.7±0.8% at 6 
months (p=0.0417) and 6.5±0.8% at 12 months (p=0.3422) after the initiation of 
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glucocorticoid therapy (Figure 2). These results showed no statistically significant change in 
HbA1c levels even after strict glucocorticoid therapy. As for patients taking medication for 






The three main findings of this study were as follows. First, a high frequency of pancreatic 
endocrine dysfunction was observed in IgG4RD patients without obvious type 1 AIP. Second, 
the pancreatic endocrine dysfunction was characterized by glucagon hyperreactivity rather than 
an insulin secretion defect. Third, no significant further deterioration of glucose tolerance due 
to intensive glucocorticoid therapy was observed in the majority of the cases. These results 
suggest that IgG4RD-related DM could be treated with glucocorticoid, probably through 
suppression of glucagon heperreactivity. 
IgG4RD sometimes exhibits type 1 AIP accompanied by both endocrine and exocrine 
dysfunction in the pancreas. Pancreatic endocrine dysfunction has been observed in 83% to 
88% of AIP [7-11]. Additionally, 66.5% of Japanese AIP cases were associated with DM; of 
those, 51.6% developed DM around the same time as the onset of AIP, and 33.3% had DM 
before the onset of AIP [8]. Following glucocorticoid therapy, 55% and 36% of these AIP 
patients showed improvement in DM control [8]. On the other hand, 14% of patients showed 
newly developed DM after corticosteroid therapy [7, 8]. However, few data exist regarding the 
impact of IgG4RD without AIP on the occurrence of DM and its treatment. The present data 
revealed that about 70% of the IgG4RD patients had DM or IGT even without obvious type 1 
AIP, which is similar to the frequency of DM associated with type 1 AIP.  
In this study, glucagon hypersecretion, rather than an insulin secretion defect, could play a 
central role in the initiation and progression of glucose intolerance in IgG4RD. This finding is 
relevant to the pathogenesis of glucose intolerance with IgG4RD, since glucagon 
hypersecretion could be the antecedent findings of general type 2 diabetic patients [25-28]. This 
finding also suggests the possible involvement of pancreatic islets in IgG4RD even (without 
AIP. Interestingly, in contrast to present results with IgG4RD without type 1 AIP, the subjects 
with this association show significant reduction in both glucagon and insulin responses against 
several stimuli including glucose and arginine [20]. The endocrine dysfunction in AIP is caused 
by fibrosis due to the inflammatory cells infiltration into the whole pancreas, resulting in 
secretion defects in the islets of α-cells and β-cells [20]. In addition, Tanaka et al. reported that 
the beta cell count decreased in AIP by immunohistologic examination [29], but did not 
mention about the change in insulin secretion. In our patients, insulin secretion was 
comparatively well maintained, indicating that a decline in beta cell count was unlikely. This 
suggests that IgG4-RD, without AIP, has a different mechanism compared with that of AIP. 
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 Some reports showed that hyperglycemia during the course of corticosteroid therapy 
occurred within three months in 5-25% of patients who started taking oral glucocorticoids 
[30-32]. Furthermore, almost all cases with glucocorticoid therapy show deterioration in 
glucose tolerance and rarely show improvement in glycemic control. The underlying molecular 
mechanisms for this glucose intolerance were accelerated hepatic glyconeogenesis, reduced 
glucose uptake in skeletal muscles, and hyperglucagonemia. It depended on the duration of 
glucocorticoid administration rather than the timing of the first dose of glucocorticoid. In our 
study, the HbA1c levels of 22 patients became significantly elevated for the first 6 months. 
After that, they improved, returning to a level not significantly different from the baseline at 12 
months. Moreover, half of the patients did not require medication for diabetes. In 11 patients 
without medication for diabetes, HbA1c levels elevated from 5.8% to 6.4% within 3 months, 
and then, declined to 6.3%. Thus, in this patient group, glucocorticoid therapy resulted in the 
elevation of HbA1c by only 0.5%. From this point of view, 11 patients taking medication for 
DM did not exhibit elevation of HbA1c after 12 months. This may be explained by the DM 
drugs taken by patients in the latter group. 
There are some limitations in the present study. First, we could not obtain histological 
findings for the pancreas in IgG4RD without obvious type 1 AIP because of difficulty in 
pancreatic tissue sampling. However, pancreatic imagings strongly suggested the absence of 
type I AIP in the present cohorts. Second, medication for DM was not consistent in this study. 
Therefore, medication for diabetes might have altered the clinical course of diabetes. However, 
the finding of HbA1c reduction even with glucocorticoid therapy, clearly showed that there was 
improvement in glucose tolerance throughout the present study.  
In conclusion, this is the first report that pancreatic endocrine dysfunction without obvious 
AIP frequently occurs in IgG4RD. Under these conditions, intensive glucocorticoid therapy is 
effective in improving glucose tolerance. We suggest that evaluation of pancreatic endocrine 
dysfunction provides clinical information indicating the early pancreatic involvement of 
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Characteristics of subjects with IgG4-related disease 
 
 
FH, family history; I.I., Insulinogenic index; NGT, normal glucose tolerance; IGT, impaired 
glucose tolerance; DM, diabetes mellitus; GL, glinide; SU, slufonylurea; αGI, αglucosydase 
inhibitor; BG, biganide; TZD, thiazolidine; DPP-4, dipeptidyl peptidase-4 inhibitor; LG, 




before CG after GC
1 65 M 29.5 3310/1420 74 LG + 9.7 DM 1.37 7.63 6.8 0 0.01 - GL, BG -




3 64 F 30.9 1820/486 90 LG + 5.6 NGT 2.72 1.73 155.6 1.04 1.80 + none none
4 46 F 29.4 1350/209 170 LG, SG - 7 DM 7.5 1.38 141.1 0.33 0.46 + αGI αGI
5 60 M 17.1 1480/463 5310 LG, Skin + 6.8 DM 0.68 13.13 14.5 0.08 1.01 + none
Insulin, GL,
αGI
6 53 F 27 2260/359 611 LG, SG + 7.2 DM 4.11 1.96 67.2 0.21 0.40 + none Insulin, GL
7 66 M 19.9 1457/173 - RP unknown 6.7 - + GL GL
8 66 M 25 1900/575 151
LG, SG,
Skin
unknown 5.6 IGT 1.34 2.71 84.5 1.47 4.00 + none none
9 76 F 27.4 2840/769 414
LG,
Kidney
- 5.9 DM 2.79 2.00 109.9 0.56 1.12 + none none
10 58 M 18.7 2850/1280 456
Kidney,
Liver
- 5.5 IGT 1.09 6.28 54.6 0.42 2.26 + GL GL
11 64 M 28.7 3070/1800 302 SG, Lung + 7.3 DM 5.86 1.40 110.3 0.22 0.31 + none Insulin, BG
12 75 F 23.1 3695/500 1226
Lung,
Kidney
- 5.6 DM 2.49 3.68 102.2 0.17 0.61 + none none
13 61 F 20.5 2152/345 1935 SG - 5.7 NGT 1.71 3.57 108.0 1.17 4.16 + none none
14 68 M 28.3 4661/1120 335 Kidney - 6.9 DM 2.63 3.18 72.0 0.28 0.89 + none unknown
15 58 F 25.2 1674/606 3 LG + 6.7 DM 2.52 2.45 66.9 0.57 1.39 + none none
16 44 M 23.3 1332/599 351 LG + 6 NGT 0.77 7.97 30.2 0.18 1.40 + none none
17 77 M 18.7 1813/438 375 SG - 5.7 IGT 1.21 69.4 0.38 2.32 + none none
18 73 M 22.8 1487/196 47 RP - 6.6 IGT 2.38 2.90 58.2 0.38 1.10 - none -
19 61 M 20.1 3323/916 1500 SG, Lung - 5.6 NGT 2.32 5.20 102.7 1.02 5.32 + none none
20 68 M 24.7 3391/736 -
Kidney,
LN
- 6 - + SU, αGI Insulin
21 61 F 24.9 1481/152 1938
Lung,
Kidney
- 6.1 DM 2.36 2.78 80.8 0.22 0.62 + none none
22 46 M 23.2 1865/860 83 LG, SG - 6 NGT 0.99 7.98 42.2 0.74 5.94 + none none
23 70 M 24.9 2081/870 1285
SG,
Prostate




24 79 F 22.5 1261/260 301 SG + 6.7 DM 1.32 6.43 43.7 0.19 1.20 + none BG, DPP-4
25 60 M 22.3 2141/1100 459
LG,
Kidney
- 6.8 DM 0.8 9.13 30.3 0.06 0.56 + SU, TZD
Insulin,
TZD
26 41 F 22.1 1554/260 134 LG + 5.1 NGT 1.06 8.14 87.4 0.98 7.94 - none -
27 64 F 26 1214/67.6 47 SG - 7.2 - - SU, αGI -






















































Comparison of the prevalence rate of DM or IGT patients with Japanese general population 





IgG4RD without obvious 
type1 AIP  
 
Age Total DM/IGT % Total DM/IGT % p* 
40-49 557 85 15.3 4 1 25.0 0.6153 
50-59 711 194 27.3 5 4 80.0 0.0145 
60-69 934 331 35.4 13 10 76.9 0.0024 
70- 1008 379 37.6 6 6 100 0.0006 
 
Data of standard population was quoted by National Health and Nutrition Survey in 2007 by 





















5 1.1 3.2 2.1 87 312 225 
6 2.7 6.7 4 134 611 477 
9 2.1 6.8 4.7 123 225 102 
11 2.6 5.1 2.5 151 731 580 
12 4.5 9.5 5 150 523 373 
14 4.5 11.1 6.6 464 1423 959 
15 3.3 11.4 8.1 140 365 225 
24 1.8 5.3 3.5 96 178 82 
25 4.6 5.9 1.3 95 248 153 
27 2.0 4.5 2.5 ND ND ND 
Mean±SD 
 
2.9±1.3 7.0±2.8 4.0±2.1 160±117 513±389 353±284 
IGT 
8 2.9 7.6 4.7 125 429 304 
17 1.0 2.6 1.6 79 183 104 
18 2.1 5.8 3.7 94 343 249 
Mean±SD 
 
2.0±1.0 5.3±2.5 3.3±1.6 99±23 318±125 219±103 
NGT 
13 1.7 8.4 6.7 128 510 382 
16 1.1 3.2 2.1 145 292 147 
19 1.8 5.5 3.7 112 218 106 
22 1.1 8.4 7.3 88 367 279 
26 1.2 5.7 4.5 71 225 154 
28 2.2 4.8 2.6 62 166 104 
Mean±SD 
 
1.5±0.5 6.0±2.1 4.5±2.1 101±33 296±126 195±112 
 















Change of HbA1c level after initiation of glucocorticoid 
 
Twenty-two patients were followed for 12 months after initiation of glucocorticoid. In 11 
patients with medication for diabetes with filled squares (■), 2 patients switched from OHAs 
to insulin, 4 patients continued OHAs, and the remaining 5 patients newly started medication 
for diabetes with OHAs or insulin. In 11 patients without medication for diabetes with filled 
triangles (▲), 4 patients were DM, 2 were IGT, and 5 were NGT. HbA1c levels of all subjects 
with filled circles (●) changed from 6.4±0.8% at baseline to 6.8±1.0% at 3 months 
(p=0.0368). HbA1c level declined to 6.7±0.8% at 6 months (p=0.0417) and 6.5±0.8% at 12 
months (p=0.3422) after the initiation of glucocorticoid therapy. * p value is <0.05 vs 
baseline. 
 
 
